GRAY News

September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx (GDRX) priced well above the range to raise $1.1 billion at a $14.2 billion market cap. The company provides one of the...read more

Graybug Vision, a Phase 2 biotech developing long-acting formulations of drugs for ocular diseases, raised $90 million by offering 5.6 million shares at $16, the midpoint of the $15 to $17 range. The company originally filed to sell 4.7 million shares, before upsizing the offering by 20%. The Redwood City, CA-based company plans to list on the Nasdaq under the symbol GRAY....read more

Graybug Vision, a Phase 2 biotech developing transformative medicines for ocular diseases, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Graybug Vision would command a fully diluted market value of $338 million. The...read more

While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders, Eli Casdin and Keith Meister, the company plans to target the life science industry, specifically businesses in the life...read more